

Translating scientific challenges into preclinical research solutions

World Vaccine Conference, Oct. 18, 2023

Konrad Stadler



Cerba Research and Viroclinics-DDL



- A Global Contract Research Organization with more than 50 years of Specialty Diagnostic and Laboratory Services.
- Specialty Services in Virology & Immunology through its specialty BU Viroclinics-DDL.
- One Stop Shop combining Routine and Specialty testing.
- Ranging from pre-clinical testing to support of Phase III studies and Global Logistics.



Our Global Footprint

A Network of Excellence

- Research & Partner labs
- Pre-Processing labs
- Office locations and Technical Platforms

USA:

New York
 Routine, Genetics/NGS, Molecular Biology, IVD, Flow Cytometry, Bioanalytical Lab/PK, Histopathology/IHC, Virology

China:

Shanghai
 Routine, Genetics/NGS, Molecular Biology, Flow Cytometry, Bioanalytical Lab/PK, Histopathology/IHC

France:

Paris & Montpellier
 Genetics/NGS, Molecular Biology, IVD, Flow Cytometry, Histopathology/IHC, Virology, Microbiology, Pre-clinical, Biorepository

Taiwan:

Taipei
 Routine, Genetics/NGS, Flow Cytometry, Histopathology/IHC Lab/PK, Histopathology/IHC

South Africa:

Johannesburg, Durban, Cape Town
 Routine, Genetics/NGS, Molecular Biology, Flow Cytometry, Histopathology/IHC, Virology, Microbiology, BSL3, Biorepository, PBMC

Australia:


Sydney
 Routine, Molecular Biology, Flow Cytometry, Virology

Belgium:


Ghent
 Routine, Molecular Biology, Bioanalytical Lab, Flow Cytometry, Microbiology

The Netherlands:

Rotterdam, Rijswijk & Schaijk
 BSL3, Pre-clinical, Molecular Biology, Genetics/NGS, Pathology, Virology



Viroclinics - a one-stop shop for vaccine research





Cerba Research



Viroclinics-DDL

A Cerba Research Company


Detection and molecular characterization of (emerging) viruses

Animal models

Laboratory assays for virus testing and evaluation of virus-specific immune responses

Viral sequencing applications – long & short read

Sequencing Applications




- ❑ Direct RNA sequencing
- ❑ Monitor quasispecies or the emergence of virus variants (combination of short and long read sequencing)
- ❑ Understand the spread of a novel virus or virus mutants through communities
- ❑ Identify conserved regions and mutational hotspots within the genome
- ❑ B-, T-cell receptor repertoires
- ❑ ... (more)

Technology



Virus



- Sars-Cov-2
- hRSV
- hMPV
- Influenza
- Dengue
- HBV/HDV/HCV
- HPV
- HIV
- CMV
- And more

Dedicated Bio-IT Team & proprietary pipeline

BIG DATA

INFORMATION



FASTQ files



Reference seq

```
>Wuhan-Hu-1
ATTAAAGGTTTA
TACCTTCCCAGG
TACAAACCA...
```




Variant table

```
A100T @ 10%
C105T @ 2%
G137A @ 87%
C223DEL @ 43%
...
```

- Substitutions (A23403G)
- Insertions (21990.1T)
- Deletions (A21766DEL)

Coverage graph (# nt per genomic position)



Consensus seq

```
>Sample14
ATTACCCGGTTT
ATACCTTCCCA
GGTACAATCCA
...
```

Joint publications FDA



Cerba Research



Viroclinics-DDL

A Cerba Research Company

Detection and molecular characterization of new viruses

Animal models

Laboratory assays for virus testing and evaluation of virus-specific immune responses

Capabilities and preclinical expertise

- 1600 m² preclinical facility in Schaijk, the Netherlands
- Conventional, BSL2 and BSL3(+) animal facility
- GAP III Polio Certificate of Participation
- Negatively-pressurized isolator cages
- Range of different animal species
- Solutions for any kind of experimental set up: challenge and transmission studies
- AAALAC-accreditation (In progress)





Research Types

- Vaccine Efficacy
- Passive Immunization
- Immunogenicity
- Transmission studies
- Antiviral Therapy/Prophylaxis
- Immunopathology
- Pathogenicity
- Pharmacokinetics
- Resistance / Mutants
- Safety
- ...(*more*)

Lab Read Outs

- Virus titer
- Virus genome copy number
- Antibody
- Cytokines
- Pathology
- Histopathology
- Genomics
- Imaging
- ... (*more*)

Development of animal models for any pathogen and research question

Virus	Mouse	Ferret *	NHP	Other
H7N9 A/Influenza	x	X		
H5N1 A/Influenza	X	X	X	Cat
pH1N1 A/Influenza	X	X**	X	Cat
H3N2 A/Influenza	X	X**		
B/Influenza	X	X		
HRSV (A and B)	X	X**	X	Cotton rat
hMPV	X		X	Hamster
SARS-CoV		X		Cat
MERS-CoV				Rabbit
SARS-CoV-2		X		Hamster, rabbits
Varizella Zoster virus			X	
Measles virus			X	Cotton rat
Monkeypox virus			X	
Rabies virus	X			
Dengue virus			X	
Polioviruses	X			
... (more)				



* Naive and pre-exposed ferrets
 ** Immunocompromised ferret model

SARS-CoV-2 Model Development Timelines

Dec
2019

First case of SARS-CoV-2 in humans reported

Mar/Apr
2020

Syrian Golden Hamster established as SARS-CoV2 animal model

Animal models for COVID-19

César Muñoz-Fontela, William E. Dowling, Simon G. P. Funnell, Pierre-S. Gsell, A. Ximena Riveros-Balta, Randy A. Albrecht, Hanne Andersen, Ralph S. Baric, Miles W. Carroll, Marco Cavaleri, Chuan Qin, Ian Crozier, Kai Dallmeier, Leon de Waal, Emmie de Wit, Leen Delang, Erik Dohm, W. Paul Duprex, Darryl Falzarano, Courtney L. Finch, Matthew B. Frieman, Barney S. Graham, Lisa E. Gralinski, Kate Guilloyle, Bart L. Haagmans, Geraldine A. Hamilton, Amy L. Hartman, Sander Herfst, Suzanne J. F. Kaptein, William B. Klimstra, Ivana Knezevic, Philip R. Krause, Jens H. Kuhn, Roger Le Grand, Mark G. Lewis, Wen-Chun Liu, Pauline Maisonnasse, Anita K. McElroy, Vincent Munster, Nadia Oreshkova, Angela L. Rasmussen, Joana Rocha-Pereira, Barry Rockx, Estefanía Rodríguez, Thomas F. Rogers, Francisco J. Salguero, Michael Schotsaert, Koert J. Stittelaar, Hendrik Jan Thibaut, Chien-Te Tseng, Julia Vergara-Alert, Martin Beer, Trevor Brasel, Jasper F. W. Chan, Adolfo García-Sastre, Johan Neyts, Stanley Perlman, Douglas S. Reed, Juergen A. Richt, Chad J. Roy, Joaquim Segalés, Seshadri S. Vasan, Ana Maria Henao-Restrepo & Dan H. Barouch

[-Show fewer authors](#)
Nature **586**, 509–515(2020) | [Cite this article](#)

Feb
2020

Virus stock available for animal model development

Apr/May
2020

First efficacy testing of a SARS-CoV2 vaccine candidate in hamsters

Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing

Authors



Joan E.M. van der Lubbe¹, Sietske K. Rosendahl Huber¹, Aneesh Vijayan¹, Liesbeth Dekking¹, Ella van Huizen¹, Jessica Vreugdenhil¹, Ying Choi¹, Miranda R.M. Baert¹, Karin Feddes-de Boer¹, Ana Izquierdo Gil¹, Marjolein van Heerden², Tim J. Dalebout¹, Sebenzile K. Myeni³, Marjolein Kikkert¹, Eric J. Snijder³, Leon de Waal⁴, Koert J. Stittelaar⁵, Jeroen T.B.M. Tolboom¹, Jan Serroyen¹, Leacky Muchene¹, Leslie van der Fits¹, Lucy Rutten¹, Johannes P.M. Langedijk¹, Dan H. Barouch⁶, Hanneke Schuitemaker¹, Roland C. Zahn¹, Frank Wegmann¹

Npj Vaccines (2021)6:39




Organoids - Complement to animal models

- ❑ Human system
- ❑ Derive from a few cells from a tissue, embryonic stem cells or induced pluripotent stem cells
- ❑ Minutuarized version of organs or tissues produced in vitro
→ recapitulate morphology and functions of their in vivo counterparts
- ❑ Study pathogen-host interaction in vitro
- ❑ Model system for drug screening, discovery and development



Human gut organoids to study SARS-CoV2 infection of the gastrointestinal tract


- COVID-19 patients experience gastrointestinal symptoms (e.g. diarrhea).
- SARS-CoV2 can be detected in stool samples (infectious particles)
- SARS-CoV2 spread via so-called 'fecal-oral transmission'.
- ACE2 is highly expressed in the intestine



Organoids(3D) were dissociated by enzymatic treatment into single cells and cultured on transwells (2D) to facilitate virus infection

SARS-CoV2 replicates in human intestinal epithelium and infects enterocytes

- ❑ Cells infected apically with SARS-CoV2
- ❑ Two different donors used
- ❑ Apical side sampled 0, 24, 48, 96 and 192 hours post infection





Cerba Research



Viroclinics-DDL

A Cerba Research Company

Detection and molecular characterization of new viruses

Animal models

Laboratory assays for virus testing and evaluation of virus-specific immune responses

ViroSpot assay – a versatile platform for high-throughput virology testing


- ❑ Used for:
 - Infectious virus titration
 - Virus neutralization and inhibition
 - Antigenic characterization of virus strains
 - Monitoring virus phenotype associated with different susceptibility

- ❑ The assay is performed with wildtype virus → gold standard for evaluation of functional antibodies


- ❑ CTL ImmunoSpot analyser
resolution of immuno-staining is sufficient to detect and count single infected cells (GLP and 21CFR part 11 compliant software)



ViroSpot to measure virus infectivity, neutralization and inhibition of virus replication





Incubation period depends on virus replication kinetics and on aim of the assay



ViroSpot assay: Influenza A virus-infected MDCK cells

- A(H3N2) strain A/Perth/16/2009
- 6h: Infected cells detectable
- 24h: comet shaped infected area in absence of solidifying agent (e.g. CMC)

well defined spots in presence of CMC



Other assays for evaluation of immune responses in pre-clinical setting

- ELISpot/FluoroSpot
 - The ELISpot assay is one of the most sensitive immunoassay for *ex vivo* enumeration of antigen-specific B and T cells secreting signature molecules (e.g. cytokines and antibodies) at the single cell level.
- ELISA
- MesoScaleDiagnostics (MSD) platform
- Luminex
- Cytotoxicity assays (LDH release, WST-8, Cell Titer Glow)



Cytokine secreting cells
(T cells)



Antibody secreting cells
(B cells)



Summary

- ❑ Viroclinics one-stop shop for vaccine research
 - ❑ Extensive experience and know-how in research on endemic and (re)emerging pathogens
 - ❑ Our research and preclinical activities encompass molecular characterization of viruses, development of animal models, and laboratory assays needed for vaccine development.
 - ❑ Viroclinics/Cerba Research is partner of the Coalition for Pandemic Preparedness Innovation (CEPI) centralized laboratory network
- 



For more information visit our booth N. 60